Related Experiment Video
Updated: Aug 14, 2025

Technique for Intranasal Administration of α-Synuclein Aggregates
Published on: November 8, 2024
Chiral Se@CeO2 superparticles for ameliorating Parkinson's disease
Ximing Liu1,2, Hongyu Zhang1,2, Changlong Hao1,2
1International Joint Research Laboratory for Biointerface and Biodetection, Jiangnan, University, Wuxi, Jiangsu, 214122, People's Republic of China. hcl@jiangnan.edu.cn.
Abstract:
In this study, we prepare chiral D-/L-type Se@CeO2 superparticles (D-/L-SPs) with a g-factor of 0.018 using D-/L-cysteine as chiral ligands. The chiral SPs demonstrate ultra-high enzyme activity of peroxidase (POD), superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx). Due to the synergistic effect between Se and CeO2, the maximum initial velocity of GPx, CAT, and POD for L-SP is 10, 7, and 5.6 times higher than that of a mixture of Se nanoparticles (NPs) and CeO2 NPs. Significantly, the chiral L-SPs show much stronger ROS scavenging ability than D-SP in the PD-like cell model. Moreover, the amount of α-synuclein (α-syn) in the cerebrospinal fluid of PD mice is reduced by 70.7% within two weeks. The L-SPs effectively alleviate neurodegeneration in a mouse model of PD, showing potential applications in the clinical treatment of neurodegenerative diseases.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease: Overview
Neural Regulation
Direct-Acting Cholinergic Agonists: Pharmacokinetics
Alzheimer's Disease: Treatment
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...

